نوع مقاله : مقاله پژوهشی
عنوان مقاله English
نویسندگان English
increase the risk of cardiac, vascular and bone diseases. Hemodialysis patients (HD) are at high risk for Scurvy disease due to dietary limitation and ascorbic acid losses through dialysis. Vitamin C also decreases HTN and accelerated arthrosclerosis. Thus, vitamin C supplementation is necessary for these patients. The aim of this study was to evaluate efficacy of oral versus intravenous vitamin C on serum oxalate level in hemodialysis patients.
Material and Methods: This clinical-trial study was done on hemodialysis patients referred to the three treatment centers of Mazandaran Province. 41 HD patients, who had not consumed vitamin C for two months, were randomly divided into two groups, oral and intravenous. In intravenous (IV AA) group, vitamin C 500 mg/day was administered three times a week; and oral group received vitamin C 125 mg/day for two months. Oxalate serum level was measured before and after treatment. Individual, laboratory, and treatment complication data were gathered in a questionnaire. Intra group comparison was done with t-student test and inter group comparison was done with independent– sample t-test. Data were expressed as SE± Mean and p-valueResults: Serum oxalate level in each group increased, there was no significant differences intra group and between two groups (p= 0.3) (in oral, from 1.8±0.4mgl/L to 1.85±0.8mgl/L, P=0.4 and in IVAA from 1.8±0.7mg/L to 2.1±0.9mg/L, P=0.3).
Conclusion: Oral and IV AA in the used dosage did not increase serum oxalate level and were safe to use as supplementation in HD patients.
کلیدواژهها English
